Open Access

Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer

  • Authors:
    • Karl R. Aigner
    • Sabine Gailhofer
    • Kornelia Aigner
  • View Affiliations

  • Published online on: April 27, 2021     https://doi.org/10.3892/mco.2021.2291
  • Article Number: 129
  • Copyright: © Aigner et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To overcome drug resistance in relapsed ovarian cancer, an isolated perfusion system was used to generate a higher local exposure to cytostatic drugs. In addition to cisplatin as the cytostatic agent of choice, the present study combined adriamycin and mitomycin in a three drugs regime due to their increased cytotoxicity under hypoxia. A total of 107 patients, including 87 patients with relapses after previous platinum‑containing therapies, 46 stage IIIC and 41 stage IV cases, were enrolled in the present study. A total of 25 patients were chemonaive, including 20 stage IIIC. The systemically pretreated patients in stage IIIC survived a median of 12.8 months, and those in stage IV 10.9 months. The overall clinical response rate of stages IIIC and IV combined was 69%. A complete decrease in ascites was found in 43% of all patients, a significant reduction in 19%. Toxicity and side effects were very mild and the bone marrow suppression was mostly grade I and never exceeded grade II. The primary clinical symptom in patients with post‑therapeutic tumor necrosis, which occurred in 10‑15% of all cases, was fever, fatigue and poor performance. The isolated hypoxic abdominal perfusion treatment is a potent instrument to break an existing chemoresistance without significant side effects with a good quality of life and comparatively long survival time.

Related Articles

Journal Cover

June-2021
Volume 14 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Aigner KR, Gailhofer S and Aigner K: Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer. Mol Clin Oncol 14: 129, 2021
APA
Aigner, K.R., Gailhofer, S., & Aigner, K. (2021). Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer. Molecular and Clinical Oncology, 14, 129. https://doi.org/10.3892/mco.2021.2291
MLA
Aigner, K. R., Gailhofer, S., Aigner, K."Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer". Molecular and Clinical Oncology 14.6 (2021): 129.
Chicago
Aigner, K. R., Gailhofer, S., Aigner, K."Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer". Molecular and Clinical Oncology 14, no. 6 (2021): 129. https://doi.org/10.3892/mco.2021.2291